| __timestamp | Geron Corporation | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 9335772 |
| Thursday, January 1, 2015 | 9574000 | 999000 |
| Friday, January 1, 2016 | 14695000 | 978000 |
| Sunday, January 1, 2017 | 8437000 | 952000 |
| Monday, January 1, 2018 | 12723000 | 956000 |
| Tuesday, January 1, 2019 | 51272000 | 8122999 |
| Wednesday, January 1, 2020 | 50052000 | 8712000 |
| Friday, January 1, 2021 | 783000 | 13980000 |
| Saturday, January 1, 2022 | 868000 | 21135000 |
| Sunday, January 1, 2023 | 123740000 | 10755000 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of companies is crucial. Geron Corporation and Iovance Biotherapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Geron Corporation experienced a dramatic increase, peaking in 2023 with a cost of revenue over 1,200% higher than its 2014 figure. In contrast, Iovance Biotherapeutics, Inc. maintained a more stable trajectory, with a notable spike in 2022, reaching a cost of revenue approximately 2.3 times higher than in 2014.
This divergence highlights the different strategic paths these companies have taken. Geron's significant rise in 2023 suggests a potential expansion or increased operational costs, while Iovance's steadier growth may indicate a more controlled scaling approach. These insights provide a window into the financial health and strategic decisions of these biotech players, offering valuable information for investors and industry analysts alike.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Takeda Pharmaceutical Company Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Geron Corporation
Walgreens Boots Alliance, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.